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Abstract 
Background: Ischemic stroke is a major disease that threatens human health in ageing population. Increasing 
evidence has shown that neuroinflammatory mediators play crucial roles in the pathophysiology of cerebral ischemia 
injury. Notch signaling is recognized as the cell fate signaling but recent evidence indicates that it may be involved 
in the inflammatory response in activated microglia in cerebral ischemia. Previous report in our group demonstrated 
hypertonic saline (HS) could reduce the release of interleukin‑1 beta and tumor necrosis factor‑alpha in activated 
microglia, but the underlying molecular and cellular mechanisms have remained uncertain. This study was aimed to 
explore whether HS would partake in regulating production of proinflammatory mediators through Notch signaling.
Results: HS markedly attenuated the expression of Notch‑1, NICD, RBP‑JK and Hes‑1 in activated microglia both 
in vivo and in vitro. Remarkably, HS also reduced the expression of iNOS in vivo, while the in vitro levels of inflamma‑
tory mediators Phos‑NF‑κB, iNOS and ROS were reduced by HS as well.
Conclusion: Our results suggest that HS may suppress of inflammatory mediators following ischemia/hypoxic 
through the Notch signaling which operates synergistically with NF‑κB pathway in activated microglia. Our study 
has provided the morphological and biochemical evidence that HS can attenuate inflammation reaction and can be 
neuroprotective in cerebral ischemia, thus supporting the use of hypertonic saline by clinicians in patients with an 
ischemia stroke.
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Background
Stroke, including ischemic stroke and hemorrhagic 
stroke, is a major cause of long-term disability and death 
throughout the world and leads to heavy socioeconomic 
pressures. An epidemiology study has reported that up 
to 67.3–80.5% of stroke cases are attributed to ischemic 
stroke [1]. Furthermore, about 2–8% of all hospitalized 
patients with ischemic stroke are caused by middle cer-
ebral artery (MCA) infarction, and the risk of neuro-
logical deterioration and death is as high as 40–80% [2]. 
Increasing evidence has shown that neuroinflammatory 
mediators, which exert deleterious effects and exacerbate 
the progression of tissue damage, play crucial roles in the 
pathophysiology of cerebral ischemia injury [3, 4]. A vari-
ety of inflammatory mediators, such as interleukin-1β 
(IL-1β), tumor necrosis factor-α (TNF-α), inducible nitric 
oxide synthase (iNOS), nitric oxide (NO), reactive oxygen 
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species (ROS) are widely thought to be derived from 
activated microglia, which is the main resident immune 
cells within the central nervous system (CNS) that play 
an important role in the development of inflammatory 
response after cerebral ischemic insults [5–7]. Therefore, 
it seems to be a progressing therapeutic strategy to sup-
press the excessive inflammatory mediators driven by 
activated-microglia in cerebral ischemia.
There is ample evidence showing that Notch signaling 
plays an important role in regulating the activation of 
immune cells such as T cells and macrophages [8–10]. 
In CNS, Notch signaling is recognized as the cell fate 
signaling which is activated when Notch receptor binds 
to its ligand, thus promoting two proteolytic cleavage 
events at the receptor. The second cleavage by γ-secretase 
enzyme complex releases the Notch intracellular domain 
(NICD), which then translocates into the nucleus where 
it binds to recombination signal sequence-binding 
protein J (RBP-JK), causing the transcriptional activation 
of Notch targeting genes including the Hairy-Enhancer 
of Split (HES) and HES-related proteins (HERP) genes 
[11–13]. However, recent evidence indicates that Notch 
signaling may participate in inflammatory response 
in activated microglia in cerebral ischemia; Indeed, 
inhibition of Notch signaling resulted in reduced cell 
numbers of activated microglia, decreased expression 
of proinflammatory cytokines and cerebral infarct size 
and improved functional outcome in a model of focal 
ischemic stroke [14, 15]. Moreover, in  vivo and in  vitro 
studies have shown that Notch signaling can regulate 
NF-κB pathway which has been widely thought to play a 
key role in inflammtory response [16, 17]. In light of the 
above, Notch signaling may be a novel and important 
target to reduce inflammatory response and thus improve 
the function in ischemic stroke.
In clinic, hypertonic saline (HS), which has been 
shown to effectively reduce intracranial pressure and 
hemispheric edema, is widely utilized in acute brain 
injuries including ischemic stroke, traumatic brain injury 
and intracranial hemorrhage [2, 18, 19]. To date, many 
reports have indicated that HS has neuroprotective 
properties and could reduce mortality after cerebral 
ischemia [20–22]. Even though the osmotic property of 
HS has been well studied in brain injury, its extraosmotic 
effect is still unclear and is being widely investigated. HS 
was reported to prevent the activation of macrophages 
and NF-κB pathway and reduce the inflammatory 
response [23–25]. Previous study in our group 
demonstrated that HS could reduce infarct size and 
decrease the release of neuroinflammatory mediators, 
IL-1β and TNF-α in activated microglia in  vivo and 
in  vitro [26]. However, the underlying molecular and 
cellular mechanisms of HS on inflammation response 
in activated microglia within cerebral ischemia have 
remained uncertain. This study was aimed to determine 
whether HS would partake in regulating production of 
proinflammatory mediators through Notch signaling in 
activated microglia in experimentally induced middle 
cerebral artery occlusion (MCAO) model of ischemic 




Adult male Sprague-Dawley (SD) rats weighing 220–
250 g were used for in vivo experiments. Transient focal 
ischemia was induced by MCAO model (2  h) using an 
intraluminal suture method. Rats were randomly divided 
into sham operated group (Sham group), MCAO group, 
MCAO  +  normal saline treatment group (NS group) 
and MCAO + 10% HS treatment group (10% HS group). 
After anesthetized achieved with an intraperitoneal 
injection of 10% chloral hydrate, rats in the sham group 
were subjected to the surgical procedures at the right 
common carotid artery (CCA) without occlusion, 
while those in the other three groups were subjected to 
right-sided middle cerebral artery occlusion (MCAO) 
using an intraluminal suture approach. Two hours after 
MCAO treatment, the rats in NS and HS group were 
continuously injected, respectively, with normal saline 
(0.3 ml/h) or 10% HS (0.3 ml/h) by intravenous infusion 
via the tail vein until the end of the experiment. The 
rats in sham group, MCAO group, NS group and 10% 
HS treatment group were further subdivided into two 
subgroups according to different treatment time points: 
12 and 24 h.
Model of cerebral ischemia
Rats were fasted with only access to water for overnight 
before subjected to the surgical procedure. Cerebral 
ischemia was induced by middle cerebral artery 
occlusion as described previously [27], but with some 
modifications. In brief, the rats were anesthetized with 
10% chloral hydrate followed by a ventral midline incision 
at the neck. CCA, external carotid artery (ECA) and 
internal carotid artery (ICA) were exposed and carefully 
blunt dissected free from the adjacent vagus nerve. Next, 
the ICA was temporally clipped, the ECA and the CCA 
were ligated and an arteriotomy was made proximally 
to the carotid bifurcation. A head-end spherical nylon 
suture was inserted through the arteriotomy and 
advanced into the ICA 17–19  mm beyond the carotid 
bifurcation. The suture, which reached the origin of the 
middle cerebral artery (MCA), was ascertained by a 
mild resistance felt. At 2 h post-MCAO, the intraluminal 
suture was withdrawn to allow reperfusion. Following 
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this, the neurologic deficits were scored on a five-point 
scale: 0, no neurologic deficit; 1, a mild focal neurologic 
deficit (failure to extend left forepaw fully); 2, a moderate 
focal neurologic deficit (circling to the left); and 3, a 
severe focal deficit (falling to the left); 4, no spontaneous 
motor activity (the rats did not walk spontaneously and 
had a depressed level of consciousness). The rats with 
neurologic deficit score of 0 and 4 were excluded from 
the study for further analysis.
Cell culture and treatment
BV-2 microglial cells received from Southern Medical 
University and identified by lectin (Sigma, St. Louis, 
MO, USA; Cat. No. L0401) were cultured in Dulbecco’s 
modified Eagle’s medium-F12 nutrient mixture 
(DMEM-F12) (Invitrogen Life Technologies Corporation, 
Carlsbad, CA, USA; Cat. No. 31330-038) supplemented 
with 10% fetal bovine serum (FBS) (Invitrogen Life 
Technologies Corporation; Carlsbad, CA, USA; Cat. 
No. 10099-141) at 37  °C in a humidified incubator with 
5% CO2/95% air. A γ-secretase enzyme inhibitor, N-[N-
(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine 
t-butyl ester (DAPT, Sigma, St. Louis, MO, USA; Cat. 
No. D5942), was utilized to suppress the activation of 
Notch signaling and the cells were divided into control 
group, oxygen glucose deprivation group (OGD group), 
oxygen glucose deprivation + DAPT (DAPT group) and 
oxygen glucose deprivation  +  hypertonic saline (HS 
group). At 1 h before hypoxia, the cells in DAPT group 
and HS group were treated with DAPT (10  µM) or HS 
(80 mM), respectively, in glucose free medium. The cells 
in the OGD group were incubated alone in the glucose 
free medium. After this, the treated cells from different 
groups were incubated in an air-tight hypoxia chamber 
with 3% O2/5% CO2 at 37  °C for 4  h. After OGD, to 
imitate the cerebral ischemia/reperfusion model in vivo, 
the cells in OGD, DAPT and HS group were incubated 
in a normoxia incubator for 1 h for re-oxygenation. The 
cells in the control group were maintained in DMEM-F12 
supplemented with 10% FBS in an incubator under 5% 
CO2. Finally, the protein from the respective group was 
extracted from the BV-2 cells and stored at −80  °C for 
western blot analysis.
Cell viability assay of BV‑2 cells
To detect the effect of DAPT and HS on the viability of 
BV-2 cells, a Cell Counting Kit-8 (CCK-8, Dojindo China 
Co., Ltd., Shanghai, China, Cat. No. CK04) was used. 
The cells were plated into 96-well microplates (104 cells/
well) and stabilized for 24  h. Then cells were divided 
into OGD  +  10  µM DAPT (DAPT), OGD  +  different 
concentrations of HS (40, 60, 80, 100, 120, 140 and 
160  mM). After this, the cells were subjected to OGD 
and re-oxygenation as described above. After that, 10 μL 
CCK-8 reagent was added to each well and incubated in 
a normoxia incubator at 37 °C for 4 h. The optical density 
was then read at 450  nm using a microplate reader. 
According to this test, the cell viability of BV-2 cells was 
not significantly changed with the HS concentration 
ranging from 40 to 80  mM (P  >  0.05), but significantly 
decreased when the concentration of HS was over 
100  mM (*P  <  0.05), especially when the concentration 
of HS was over 120 mM (**P < 0.01). 10 μM DAPT had 
no significant effect on BV-2 cells viability (P  >  0.05), 
even though it was reported to be able to inhibit Notch 
signaling pathway at this concentration [17]. The data 
are shown in Additional file  1. Therefore, 80  mM HS 
and 10 μM DAPT were chosen in this study and for all 
subsequent analysis.
Western blotting
A total of 40 rats (n =  5 for each group) were used for 
western blotting. Total proteins from the peri-infarction 
cerebral cortex and BV-2 cells were extracted using a 
Total Protein Extraction Kit (Bei Jing Pu Li Lai Gene 
Technology Co., Ltd., Beijing China; Cat. No. P1053) 
following the manufacturer’s protocols. Protein concen-
trations were determined by a BCA Protein Assay kit 
(Shanghai Biocolor Bioscience and Technology Co. Ltd., 
Shanghai, China; PC0020). With addition of samples 
loading-buffer, protein samples were heated to 95 °C for 
5  min and then equal amounts of protein were loaded 
on sodium dodecyl sulfate-polyacrylamide gel for elec-
trophoresis. After electrophoresis, the protein was elec-
troblotted onto polyvinylindene difluoride membrane 
and blocked with 5% non-fat dry milk in 0.1% tween-
20 Tris-buffered saline for 1  h at room temperature. 
The membranes were then incubated with the follow-
ing primary antibodies: Notch-1 (1:500, Cell Signaling 
Technology, Danvers, MA, USA; Cat. No. 4380), NICD 
(1:300, Cell Signaling Technology, Danvers, MA, USA; 
Cat. No. 4147), RBP-JK (1: 500, Abcam, Cambridge, 
MA, USA; Cat. No. ab180588), Hes-1 (1:500, Cell Sign-
aling Technology, Danvers, MA, USA; Cat. No. 11988), 
iNOS (Santa Cruz Biotechnology, CA, USA; Cat. No. 
sc-650), Phos-NF-κB (1:1000, Cell Signaling Technology, 
Danvers, MA, USA; Cat. No. 3033) and β-actin (1:2000, 
Cell Signaling Technology, Danvers, MA, USA; Cat. No. 
3700) overnight at 4 °C. After washing with 0.1% tween-
20 Tris-buffered saline, the membranes were incubated 
with the goat anti-rabbit IgG-HRP (1:1000, Cell Signaling 
Technology, Danvers, MA, USA; Cat. No. 7074) or goat 
anti-mouse IgG-HRP (1:2000, Cell Signaling Technology, 
Danvers, MA, USA; Cat. No. 7076) secondary antibodies 
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for 2  h at 4  °C. The immunoblots were developed by a 
chemiluminescence kit (BeiJing Pu Li Lai Gene Technol-
ogy Co., Ltd., Beijing, China; P1010) and detected by an 
imaging densitometer (ImageQuant LAS 500, GE Health-
care Bio-Sciences AB, Uppsala, Sweden). Antibodies used 
in experiments is shown in Table 1. The relative density 
was quantified by FluorChem 8900 software (version 
4.0.1, Alpha Innotech Corporation, San Leandro, CA, 
USA). In addition, the results were normalized by parallel 
western blots of β-actin and all the experiments were car-
ried out in triplicate.
Double immunofluorescence labeling
At 24  h after reperfusion, 20 rats (n  =  5 each group) 
were deeply anesthetized with 10% chloral hydrate and 
transcardially perfused with normal saline rapidly fol-
lowed by 4% paraformaldehyde (Bei Jing Leagene Biosci-
ence and Technology Co. Ltd., Beijing, China; DF0135). 
The brain was removed and the frozen coronal sections 
of 10 μm thickness were cut. The sections were washed 3 
times with phosphate-buffered saline (PBS), and blocked 
with 5% bovine serum albumin (BSA) for 1  h at room 
temperature. After rinsing with PBS, the brain sections 
were incubated with the following primary antibodies: 
Notch-1 (1:100, Cell Signaling Technology, Danvers, MA, 
USA; Cat. No. 4380), NICD (1:100, Cell Signaling Tech-
nology, Danvers, MA, USA; Cat. No. 4147), RBP-JK (1: 
100, Abcam, Cambridge, MA, USA; Cat. No. ab180588), 
Hes-1 (1:100, Cell Signaling Technology, Danvers, MA, 
USA; Cat. No. 11988), iNOS (1:100, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA; Cat. No. sc-650), NF-κB 
(1:100, Cell Signaling Technology, Danvers, MA, USA; 
Cat. No. 3033) at 4  °C for overnight. On the following 
day, the sections were washed in PBS, and then incu-
bated with the secondary antibodies Alexa Fluor® 555 
Goat Anti-Rabbit IgG (H  +  L) (1:200; Invitrogen Life 
Technologies Corporation; Carlsbad, CA, USA; Cat. No. 
A-21428) and FITC-conjugated Lectin (1:100, Sigma, St. 
Louis, MO, USA; Cat. No. L0401), which bind to micro-
glia and blood vessel endothelial cells, for 2  h at room 
temperature. The nucleus was stained by 4,6-diamidino-
2-phenylindole (DAPI) for 20  min. The sections were 
mounted with a fluorescent mounting medium and 
detected with a fluorescence microscope (Olympus DP73 
Microscope, Olympus, Tokyo, Japan).
BV-2 cells seeded on the cover slips were fixed in 4% 
paraformaldehyde for 30  min, and then blocked by 5% 
BSA for another 30  min. Subsequently, the cover slips 
with the adherent cells were incubated with the primary 
antibodies as mentioned above at 4  °C overnight. After 
rinsing in PBS for 3 times the next day, the coverslips 
were incubated with the secondary antibodies and lectin 
as described above. Then the cover slips were incubated 
with DAPI for 10  min and mounted with a fluores-
cent mounting medium. All cover slips were viewed for 
labeled cells using a fluorescence microscope (Olympus 
DP73 Microscope, Olympus, Tokyo, Japan).
Measurement of reactive oxygen species
The production of ROS in BV-2 cells of different 
groups was evaluated by the 5-(and-6)-chloromethyl-
2,7-dichlorodihydrofluorescein diacetate probe 
(CM-H2DCFDA, Nanjing KeyGEN Biotech. CO., 
Ltd. Cat. No. KAGF018) following the manufacturer’s 
instruction, fluorescent images were taken by the 
fluorescent microscope (Nikon TI-S microscpe, Nikon, 
Tokyo, Japan).
Data analysis
All data was analyzed by SPSS 13.0 using one-way analysis 
of variance (ANOVA). The intergroup comparisons were 
analyzed by the least-significant-difference (LSD) and the 
Student’s Newman–Keuls (SNK) tests. Differences were 
considered statistically significant if P < 0.05.
Results
10% HS suppressed the protein expression of Notch 
signaling pathway in vivo
To explore the effects of 10% HS on the Notch pathway, 
the protein expression of members of Notch signaling 
pathway including Notch-1, NICD, RBP-JK and Hes-1 in 
the peri-ischemic cortex of ischemia rats given treatment 
of NS or 10% HS for 12 or 24 h was detected by western 
blotting. The results showed that the protein expression 
levels of Notch-1, NICD, RBP-JK and Hes-1 were sig-
nificantly increased following ischemia–reperfusion (I/R) 
(*P  <  0.05). The protein expression of Notch-1, NICD, 
RBP-JK and Hes-1 in the normal saline treated rats had 
no significant difference compared with the I/R rats 
(P > 0.05). On the contrary, the increased protein expres-
sion of Notch-1, NICD, RBP-JK and Hes-1 following I/R 
was significantly reduced with treatment of 10% HS at 12 
and 24 h (#P < 0.05) (Figs. 1a–c, 2a–c).
Table 1 Antibodies used for western blotting and staining
Antibody Host Source Catalog number
Notch‑1 Rabbit CST, Danvers, MA, USA 4380
NICD Rabbit CST, Danvers, MA, USA 4147
RBP‑JK Rabbit abcam, Cambridge, MA, USA ab180588
Hes‑1 Rabbit CST, Danvers, MA, USA 11,988
iNOS Rabbit Santa Cruz Biotechnology, 
CA, USA
sc‑650
Phos‑NF‑κB Rabbit CST, Danvers, MA, USA 3033
β‑actin Mouse CST, Danvers, MA, USA 3700
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Fig. 1 10% HS attenuates the expression of Notch‑1 and NICD in peri‑ischemic brain tissue. a The immunoreactive bands of Notch‑1 (120 kDa), 
NICD (110 kDa), and β‑actin (42 kDa), respectively. Bar graphs b, c show the protein expression of Notch‑1 and NICD are significantly up‑regulated 
in I/R and NS peri‑ischemic brain tissues compared to the sham group (*P < 0.05) at 12 and 24 h; however, it is markedly attenuated following 
treatment with 10% HS at 12 h or 24 h (#P < 0.05). The values represent the mean ± SD in triplicate. d The immunofluorescence of Notch‑1 (G, J, M, 
P, red), lectin+ microglia (F, I, L, O, green) and the co‑localization of Notch‑1 and microglia (H, K, N, Q). e The immunofluorescence of NICD (G, J, M, 
P, red), lectin+ microglia (F, I, L, O, green) and the co‑localization of NICD and microglia (H, K, N, Q). The results also show that Notch‑1 and NICD in 
activated microglia cells around the peri‑ischemia cortex are markedly increased in I/R and NS rats and decreased following treatment with 10% HS 
for 24 h. HS hypertonic saline, I/R ischemic–reperfusion injury, NS normal saline, NICD Notch intracellular domain, ns no significant difference. Scale 
bars in F–Q 20 μm
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Fig. 2 10% HS attenuates the expression of RBP‑JK and Hes‑1 in peri‑ischemic brain tissue. a The immunoreactive bands of RBP‑JK (56 kDa), Hes‑1 
(37 kDa) and β‑actin (42 kDa), respectively. Bar graphs b, c show the protein expression of RBP‑JK and Hes‑1 are significantly up‑regulated in I/R and 
NS peri‑ischemic brain tissues compared to the sham group (*P < 0.05) at 12 and 24 h; however, it is markedly attenuated following treatment with 
10% HS at 12 and 24 h (#P < 0.05). The values represent the mean ± SD in triplicate. d The immunofluorescence of RBP‑JK (G, J, M, P, red), lectin+ 
microglia (F, I, L, O, green) and the co‑localization of RBP‑JK and microglia (H, K, N, Q). e The immunofluorescence of Hes‑1 (G, J, M, P, red), lectin+ 
microglia (F, I, L, O, green) and the co‑localization of Hes‑1 and microglia (H, K, N, Q). Note that the expression of RBP‑JK and Hes‑1 in activated 
microglia cells around the peri‑ischemia cortex are markedly increased in I/R and NS rats and decreased following treatment with 10% HS 24 h. HS 
hypertonic saline, I/R ischemic–reperfusion injury, NS normal saline, RBP‑JK recombination signal sequence‑binding protein J, Hes‑1 Hairy‑Enhancer 
of Split‑1. ns no significant difference. Scale bars in F–Q 20 μm
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10% HS suppressed the Notch signaling pathway 
in activated microglia following ischemia–reperfusion 
injury
To investigate whether 10% HS would suppress the 
Notch signaling pathway in microglia, expression of 
Notch-1, NICD, RBP-JK, Hes-1 in the microglia around 
the peri-ischemia cortex of I/R injury rats given NS 
or 10% HS treatment at 24  h was examined by double 
immunofluorescence. The immunofluorescence of 
Notch-1, NICD, RBP-JK, Hes-1 in activated microglia 
around the peri-ischemia cortex in I/R rats and 
NS rats was noticeably enhanced. Additionally, the 
immunofluorescence of Notch-1, NICD, RBP-JK, and 
Hes-1 was evidently reduced following treatment of 10% 
HS for 24 h (Figs. 1d, e, 2d, e).
10% HS inhibited iNOS expression in peri‑ischemic cortex
The protein expression of iNOS was significantly 
increased following I/R injury at 12 and 24 h compared 
to sham group (*P < 0.05), while no significant decrease 
was observed for the normal saline treatment group at 
either time point (P  >  0.05). On the other hand, a sig-
nificant reduction occurred with 10% HS treatment for 
12 and 24 h compared to I/R and NS groups (#P < 0.05) 
(Fig. 3a, b). Immunofluorescence images showed a mark-
edly increased expression of iNOS in activated microglia 
in peri-ischemia cortex of rats following I/R, and in rats 
given normal saline treatment. Very strikingly, iNOS 
expression in activated microglia was reduced with 10% 
HS treatment at 24 h (Fig. 3c).
HS suppressed the Notch signaling pathway 
in hypoxia‑activated BV‑2 microglia in vitro
To investigate the effects of HS on activated microglia 
in vitro, BV-2 microglia cells were subjected to OGD for 
4  h following the treatment of HS or DAPT. The pro-
tein expression of members of Notch signaling pathway 
including Notch-1, NICD, RBP-JK, and Hes-1 were sig-
nificantly increased in BV-2 cells following OGD treat-
ment (*P < 0.05). The protein expression level of Notch-1 
was moderately depressed with the treatment of 10 μM 
DAPT and was markedly depressed with the treatment 
of 80  mM HS in OGD BV-2 cells (#P  <  0.05). The pro-
tein expression of NICD, RBP-JK, and Hes-1 were sig-
nificantly suppressed with the treatment of 80  mM HS 
or 10 μM DAPT in OGD-activated BV-2 cells (#P < 0.05) 
(Figs. 4a–c, 5a–c).
The immunofluorescence of Notch-1, NICD, RBP-jk, 
and Hes-1 was noticeably enhanced in OGD BV-2 
microglia cells at 4  h; but the immunofluorescence of 
Notch-1, NICD, RBP-JK, and Hes-1 was suppressed 
in OGD BV-2 cells with the treatment of 80 mM HS or 
10 μM DAPT (Figs. 4d, e, 5d, e).
HS and DAPT reduced the expression of inflammatory 
cytokines Phos‑NF‑κB, iNOS and ROS in hypoxia‑activated 
BV‑2 microglia
The changes of inflammatory mediators Phos-NF-κB, 
iNOS and ROS were evaluated in BV-2 microglia cells 
subjected to OGD for 4 h and following the treatment of 
80 mM or 10 μM DAPT. The protein expression of iNOS 
and Phos-NF-κB was significantly increased (*P < 0.05); 
however, the expression level of iNOS and Phos-NF-κB 
was significantly depressed with the treatment of 80 mM 
or 10 μM DAPT (#P < 0.05) (Fig. 6a–c).
Phos-NF-κB expression was markedly enhanced and 
translocated to the nucleus in OGD BV-2 microglia cells 
at 4  h. It was evidently depressed in OGD BV-2 cells 
with the treatment of 80 mM HS or 10 μM DAPT. The 
immunofluorescence of iNOS and ROS was increased 
simultaneously with Phos-NF-κB in OGD BV-2 
microglial cells at 4 h. Moreover, the expression of iNOS 
and ROS was suppressed with the treatment of 80  mM 
HS or 10 μM DAPT (Fig. 6d–f).
Discussion
It is unequivocal from the present results that HS can 
modulate Notch signaling and thence suppress NF-κB-
mediated proinflammatory cytokine production in 
activated microglia. Indeed, HS can suppress Notch 
signaling as manifested by the decreased protein 
expression of Notch-1, NICD, RBP-JK and Hes-1 in 
peri-ischemia area and OGD activated BV-2 cells. Our 
previous study suggested that HS can suppress the 
release of inflammatory mediators TNF-α and IL-1β 
in activated microglia and reduce the infarct size and 
brain water content following cerebral ischemia [26]. 
Here, we further extended the study showing that HS 
inhibits inflammatory mediator iNOS following cerebral 
ischemic–reperfusion injury at 12 and 24 h. Additionally, 
the expression of Phos-NF-κB, iNOS and ROS in 
OGD-activated BV-2 microglia was decreased with the 
treatment of 80 mM HS in vitro.
Recent studies reported that Notch signaling can be 
activated following brain injury [28] and is involved in 
the release of neuroinflammatory mediators in activated 
microglia [14]. Here, we show that Notch signaling path-
way is activated as evidenced by the up-regulation of 
Notch-1, NICD, RBP-JK and Hes-1 in activated microglia 
in experimentally induced cerebral ischemia and OGD 
induced activated BV-2 microglia. An earlier report sug-
gested that Notch-1 antisense mice exhibit significantly 
lower numbers of activated microglia and reduced proin-
flammatory cytokine expression in the ipsilateral ischemic 
cortices compared to non-Tg mice [29]. Other studies 
showed that inhibition of Notch pathway reduced the 
damage to brain cells and improved functions. Notch can 
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Fig. 3 10% HS attenuates the expression of inflammatory mediator iNOS in peri‑ischemic brain tissue. a iNOS (130 kDa) and β‑actin (42 kDa) 
immunoreactive bands, respectively. b The protein expression of iNOS in I/R and NS rats is significantly up‑regulated when compared to the sham 
group at 12 and 24 h after reperfusion (*P < 0.05); however, iNOS protein expression is drastically attenuated following treatment with 10% HS at 
12 and 24 h when compares to I/R group and NS group (*P < 0.05); The values represent the mean ± SD in triplicate. Immunofluorescence images 
show the expression of iNOS (red) and lectin+ microglia (green) in the sham group (D–F) and in the penumbral zones of I/R group (G–I), NS group 
(J–L), and HS group (M–O) after reperfusion for 24 h. Note that there is a noticeable increase of iNOS expression in activated microglia around the 
peri‑ischemia cortex in I/R and NS rats. however, iNOS expression is depressed in activated microglia following treatment with 10% HS 24 h. HS 
hypertonic saline, I/R ischemic–reperfusion injury, NS normal saline, ns no significant difference. Scale bars in D–O 20 μm
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endanger neurons by modulating pathways that increase 
their vulnerability to apoptosis, and by activating micro-
glial cells and stimulating the infiltration of proinflam-
matory leukocytes [15, 16, 30]. In the present study, we 
show that when Notch signaling is inhibited by DAPT 
(a γ-secretase inhibitor), the expression of Phos-NF-κB, 
iNOS and ROS was significantly decreased. It is evident 
that DAPT can block the Notch signaling as shown by sig-
nificantly reduction in NICD protein levels and expression 
of RBP-JK, Hes-1 expression in BV-2 microglia.
Furthermore, we have shown that HS suppresses the 
activation of Notch signaling and attenuates expression 
of members of Notch signaling in activated microglia in 
peri-ischemia tissue and hypoxic BV-2 Microglia. Addi-
tionally, we have shown by double immunofluorescence 
results that the nuclear translocation of NICD, RBP-JK 
and Hes-1 is down-regulated in activated microglia fol-
lowing treatment of HS in vivo and in vitro. This suggests 
that HS disrupts Notch signaling not only by down-
regulating the Notch receptor but also the activation of 
F  Control 4h  Lectin G  Control 4h  Notch-1 H  Control 4h  Merge F  Control 4h  Lectin G  Control 4h  NICD H  Control 4h  Merge
L  DAPT 4h  Lectin M  DAPT 4h  Notch-1 N DAPT 4h  Merge
I  OGD 4h  Lectin J  OGD 4h  Notch-1 K OGD 4h  Merge I  OGD 4h Lectin J  OGD 4h  NICD K  OGD 4h  Merge
L  DAPT 4h  Lectin M  DAPT 4h  NICD N  DAPT 4h  Merge









Fig. 4 HS attenuates the expression of Notch‑1 and NICD in hypoxia‑activated BV‑2 microglia. a The immunoreactive bands of Notch‑1 (120 kDa), 
NICD (80 kDa) and β‑actin (42 kDa), respectively. Bar graph b shows the protein expression of Notch‑1 are significantly up‑regulated in OGD 
BV‑2 cells compared to control group (*P < 0.05); but it is moderately suppressed following treatment with 10 μM DAPT (#P < 0.05) and mark‑
edly suppressed following treatment with 80 mM HS (#P < 0.05). Bar graph c show the protein expression of NICD is significantly increased in 
OGD BV‑2 cells compared to control group (*P < 0.05); however, it is decreased following treatment with 80 mM HS or 10 μM DAPT (#P < 0.05). 
The values represent the mean ± SD in triplicate. d The immunofluorescence of Notch‑1 (G, J, M, P, red), lectin+ microglia (F, I, L, O, green) and the 
co‑localization of Notch‑1 in BV‑2 microglia (H, K, N, Q). e The immunofluorescence of NICD (G, J, M, P, red), lectin+ microglia (F, I, L, O, green) and 
the co‑localization of NICD in BV‑2 microglia (H, K, N, Q). The results are consistent with the western blotting. Note that the expression of Notch‑1 
and NICD are increased in OGD‑activated BV‑2 cells and decreased with the treatment of 80 mM HS or 10 μm DAPT. HS hypertonic saline, DAPT 
N‑[N‑(3,5‑difluorophenacetyl)‑1‑alanyl]‑S‑phenylglycine t‑butyl ester, OGD oxygen glucose deprivation. NICD Notch intracellular domain. Scale bars 
in F–Q 20 μm
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Notch signaling. During the maturation of Notch1 pro-
tein, a 300-kDa precursor molecule of Notch receptor is 
constitutively cleaved by furin-like convertase [31]. Once 
Notch receptor binds to its ligand, the Notch signal-
ing will be activated by two protease hydrolysis process: 
i) the first one is catalyzed by an ADAM-type metallo-
protease at the extracellular part of Notch receptor; ii) 
the second one is catalyzed by γ-secretase containing a 
complex at the transmembrane region that releases the 
NICD which represents the activation of Notch signal-
ing [11, 12]. It is suggested that HS may act on furin-like 
convertase thus suppressing the expression of Notch-1 
and may act through the two key enzymes (ADAM-type 
metalloprotease, γ-secretase) thus inhibiting the expres-
sion of NICD, RBP-JK and Hes-1.
It has been suggested that Notch and NF-κB pathways 
operate synergistically in microglia activation and 
function [32, 33]. It is well known that the function of 
microglia is defensing of neural parenchyma, removing 
cellular debris not only during normal development 
but also in pathological conditions; in addition to 
scavenging function, activated-microglia exert a robust 
G  Control 4h RBP-JK H  Control 4hMergeF  Control 4h  Lectin G  Control 4h Hes-1 H  Control 4h  MergeF  Control 4h Lectin
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Fig. 5 HS attenuates the expression of RBP‑JK and Hes‑1 in hypoxia‑activated BV‑2 microglia. a The immunoreactive bands of RBP‑JK (56 kDa), Hes‑1 
(37 kDa) and β‑actin (42 kDa), respectively. Bar graph b, c show the protein expression of RBP‑JK and Hes‑1 are significantly increased in OGD BV‑2 
cells compared to control group (*P < 0.05); but, it is decreased following treatment with 80 mM HS or 10 μM DAPT (#P < 0.05). The values represent 
the mean ± SD in triplicate. d The immunofluorescence of RBP‑JK (G, J, M, P, red), lectin+ microglia (F, I, L, O, green) and the co‑localization of RBP‑JK 
in BV‑2 microglia (H, K, N, Q). e The immunofluorescence of Hes‑1 (G, J, M, P, red), lectin+ microglia (F, I, L, O, green) and the co‑localization of Hes‑1 
in BV‑2 microglia (H, K, N, Q). The results are aslo consistent with the western blotting. Note that the expression of RBP‑JK and Hes‑1 are increased in 
OGD‑activated BV‑2 cells and decreased with the treatment of 80 mM HS or 10 μm DAPT. HS hypertonic saline, DAPT N‑[N‑(3,5‑difluorophenacetyl)‑
1‑alanyl]‑S‑phenylglycine t‑butyl ester, OGD oxygen glucose deprivation. NICD Notch intracellular domain, RBP‑JK recombination signal sequence‑
binding protein J, Hes‑1 Hairy‑Enhancer of Split‑1. Scale bars in F–Q 20 μm
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Fig. 6 HS and DAPT reduced the expression of inflammatory mediators Phos‑NF‑κB, iNOS and ROS in hypoxia‑activated BV‑2 microglia. a The 
immunoreactive bands of Phos‑NF‑κB (65 kDa), iNOS (130 kDa), and β‑actin (42 kDa), respectively. Bar graph b, c show the expression level of Phos‑
NF‑κB and iNOS are significantly increased in OGD BV‑2 cells (*P < 0.05) and significantly depressed following treatment with 80 mM HS or 10 μM 
DAPT (#P < 0.05). The values represent the mean ± SD in triplicate. d The immunofluorescence of Phos‑NF‑κB (H, K, N, Q, red) and its co‑localization 
within the nucleus of BV‑2 cells (I, L, O, R); e The immunofluorescence of iNOS (H, K, N, Q, red); lectin+ microglia (G, J, M, P, green) and the co‑local‑
ization of lectin and iNOS (I, L, O, R); f shows the immunofluorescence of ROS (G, H, I, J, green); Note that the expression of Phos‑NF‑κB is markedly 
increased and translocated to the nucleus in OGD‑activated BV‑2 cells and decreased with the treatment of 80 mM HS or 10 μm DAPT. The expres‑
sion of iNOS and ROS is also markedly increased in parallel with Phos‑NF‑κB in OGD BV‑2 cells and depressed significantly following treatment with 
80 mM HS or 10 μm DAPT. DAPI‑blue; HS hypertonic saline, DAPT N‑[N‑(3,5‑difluorophenacetyl)‑1‑alanyl]‑S‑phenylglycine t‑butyl ester, OGD oxygen 
glucose deprivation. Scale bars in F–Q 20 μm
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inflammatory response [34–36]. NF-κB is widely thought 
to be an important regulator of neuroinflammatory 
and is crucial in cerebral ischemia [37–39]. Activated 
NF-κB is translocated to the nucleus to combine with 
proinflammatory genes such as TNF-α, IL-1β, IL-6, IL-8, 
iNOS and cyclo-oxygenase-2, which consequently results 
in expanded inflammatory reaction [40]. Transgenic 
mice deficient in the NF-κB subunit or pharmacological 
inhibition of the NF-κB pathway develop significantly 
smaller infarcts after middle cerebral artery occlusion 
[41, 42]. Some studies have considered that Notch is 
the upstream of NF-κB [16, 17]. It has been reported 
that γ-secretase-mediated Notch signaling acts to keep 
NF-κB activity and release of inflammatory in peripheral 
T cells; inhibition of Notch with pharmacological 
attenuates the nuclear distribution of NF-κB, thus 
reducing transcriptional activity [43]. On the other 
hand, Notch signaling can up-regulate the expression of 
the active NF-κB signaling components, thus enhancing 
NF-κB activation [44]. Here, we showed that the protein 
expression and nuclear translocation of NF-κB was 
significantly down-regulated in BV-2 microglia when 
Notch signaling was inhibited by DAPT.
In addition, we show that HS can inhibit the expres-
sion of NF-κB by Western blot; the nuclear transloca-
tion of NF-κB is also down-regulated with treatment of 
80  mM HS in OGD-activated microglia by immunoflu-
orescence. In parallel to NF-κB, the expression of iNOS 
and ROS was significantly decreased with the treatment 
of HS. Inflammatory mediators are thought to be vital in 
acute and chronic brain injury, such as stroke [45], Alz-
heimer’s disease [46] and Parkinson’s disease [47]. Exces-
sive release of proinflammatory mediators can lead to 
neuronal death, glia activation, synaptic impairment and 
exacerbate neurodegenerative disorders. iNOS and ROS 
are known to be involved in oxidative stress that was indi-
cated to contribute to the death of neurons and glia [48, 
49]. Activated microglial cells are thought to be the main 
origin of inflammatory mediators and crucially involved 
in neuronal damage in the penumbra in ischemia stroke 
[5–7]. Our previous study had shown that HS could sup-
press the release of inflammatory mediators, namely, 
TNF-α and IL-1β in activated microglia [26]. Here, we 
show that HS can suppress the release of NF-κB medi-
ated iNOS and ROS. It is relevant to note that hypertonic 
treatment decreases I-kBα phosphorylation and thus 
decreases NF-κB nuclear translocation and activation 
[25]. In light of present finding, it is suggested that HS 
inhibits production of NF-κB mediated proinflammatory 
mediators in activated microglia by disrupting the Notch 
signaling.
As far as can be ascertained, this is the first 
report which demonstrates that HS participates in 
Notch-dependent inflammatory changes associated 
with cerebral ischemia. Arising from the above, we sug-
gest that HS can be helpful in diminishing the neuronal 
damage caused by excessive neuroinflammation follow-
ing ischemia–reperfusion injury. Furthermore, because 
inflammation mediators are also implicated in other 
brain damages such as disruption of blood-brain barrier, 
it stands to reason that hypertonic saline would also be 
beneficial to restore these functions that are expected to 
be compromised in cerebral ischemic. Thus, HS could be 
a potential therapeutic option for amelioration of micro-
glia–mediated neuroinflammation and thence improving 
neurological function in cerebral ischemia.
Conclusion
We show here that HS can suppress Notch signaling 
and proinflammatory mediators such as Phos-NF-κB, 
iNOS and ROS in activated microglia. Pharmacological 
inhibition of Notch signaling attenuates the expression 
of Phos-NF-κB, iNOS and ROS. In consideration of the 
present results along with others, it is suggested that 
HS may suppress of inflammatory mediators following 
ischemia/hypoxic through the Notch signaling which 
operates synergistically with NF-κB pathway in activated 
microglia. Our study has added new evidence that HS can 
attenuate inflammation and this can be neuroprotective 
in cerebral ischemia, thus adding a morphological basis 
at the cellular level for clinicians in the use of hypertonic 
saline in patients with an ischemic stroke.
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